CS-1008 Used With Irinotecan Versus Irinotecan Alone in Subjects With Metastatic Colorectal Carcinoma Who Failed First-line Treatment With Oxaliplatin

NCT ID: NCT00969033

Last Updated: 2012-01-31

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE2
• Total Enrollment: 8 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2009-07-31
• Study Completion Date: 2011-12-31

Brief Summary

The purpose of this study is to determine the effect of CS-1008 in combination with irinotecan compared to irinotecan alone on Progression-Free Survival (PFS) in subjects with metastatic or advanced colorectal cancer (CRC) who have failed oxaliplatin-based first-line treatment.

Conditions

Metastatic Colorectal Cancer

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

CS-1008 with irinotecan

CS-1008 and irinotecan

Group Type: EXPERIMENTAL

CS-1008

Intervention Type: DRUG

CS-1008

irinotecan

Intervention Type: DRUG

irinotecan

irintoecan

irinotecan alone

Group Type: ACTIVE_COMPARATOR

irinotecan

Intervention Type: DRUG

irinotecan

Interventions

CS-1008

CS-1008

Intervention Type: DRUG

irinotecan

irinotecan

Intervention Type: DRUG

Other Intervention Names

Camptosar

Eligibility Criteria

Inclusion Criteria

• Histologically confirmed CRC which is now metastatic and after failure of oxaliplatin-based first-line treatment.
• At least 18 years of age.
• ECOG performance status =< 1.
• Measurable disease based on RECIST criteria.
• Adequate organ and bone marrow function as evidenced by:

• Hemoglobin >= 9.0 g/dL (may be transfused to this level)
• Absolute neutrophil count (ANC) >= 1.5 x 109/L
• Platelet count >= 100 x 109/L
• Serum creatinine =< upper limit of normal (ULN) or creatinine clearance > 50 mL/min
• AST <= 2.5 x ULN in subjects with no liver metastasis and <= 5.0 x ULN in subjects with liver metastasis
• Total bilirubin < 1.5 x ULN
• Men and women of childbearing potential must be willing to consent to using effective contraception (e.g., hormonal contraceptives, bilateral tubal ligation, barrier with spermicide, intrauterine device) while on treatment and for 3 months thereafter.
• All female subjects of childbearing potential must have a negative pregnancy test (serum or urine) result within 7 days before initiating study treatment.
• Subjects must be fully informed about their illness and the investigational nature of the study protocol (including foreseeable risks and possible side effects) and must sign and date an IEC/IRB approved ICF before performance of any study specific procedures or tests.
• Subjects must be willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

Exclusion Criteria

• Anticipation of need for a major surgical procedure or radiotherapy (RT) during the study.
• Treatment with chemotherapy hormonal therapy, RT, minor surgery, or any investigational agent within 4 weeks before study enrollment. Treatment with nitrosoureas, mitomycin C, immunotherapy, biological therapy, or major surgery within six weeks prior to study enrollment. St John's Wort within 2 weeks prior to study enrollment or during the study.
• History of any of the following conditions within 6 months before study enrollment:

• Clinically significant myocardial infarction or severe/unstable angina pectoris
• New York Heart Association (NYHA) class III or IV congestive heart failure (Section 17.2)
• Clinically significant cerebrovascular accident, transient ischemic attack or pulmonary embolism- Clinically significant pulmonary disease (e.g., severe chronic obstructive pulmonary disease or asthma)
• Presence of any of the following: Symptomatic brain metastasis; an uncontrolled seizure disorder; spinal cord compression; or carcinomatous meningitis.
• Clinically significant active infection that requires antibiotic therapy or Human Immunodeficiency Virus (HIV) positive subjects receiving antiretroviral therapy.
• History of malignancy other than CRC, unless there is the expectation that the malignancy has been cured, and tumor specific treatment for the malignancy has not been administered within the previous 5 years. Exceptions to this are non melanotic cancer of the skin and adequately treated carcinoma of the cervix-in-situ.
• Previous treatment with CS 1008, other agonistic DR5 antibody agents, or TRAIL agents.
• History of active chronic inflammatory bowel disease and/or bowel obstruction within the last 3 months.
• Pregnant or breast feeding.
• Known history of hypersensitivity reactions to irinotecan or to one of the excipients.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Daiichi Sankyo

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Broomfield Hospital

Chelmsford, Essex, United Kingdom

Mount Vernon Hospital

Northwood, Middlesex, United Kingdom

Nottingham City Hospital

Nottingham, Notts, United Kingdom

Chrichill Hospital

Oxford, Oxon, United Kingdom

Royal Marsden Hospital

Sutton, Surrey, United Kingdom

Clatterbridge Hospital

Bebington, Wirral, United Kingdom

Royal United Hospital Bath

Bath, , United Kingdom

Russels Hall Hospital

Dudley, , United Kingdom

Leicester Royal Infirmary

Leicester, , United Kingdom

Countries

United Kingdom

Other Identifiers

CS1008-A-E203

Identifier Type: -

Identifier Source: org_study_id